chromomycin A5

Chromomycin A5 is a member of the aureolic acid family of antitumor antibiotics, structurally related to chromomycin A3, and is isolated from marine Streptomyces species[2]. Chromomycin A5 acts as a DNA-binding agent, interacting primarily with cytosine- and guanine-rich regions in the minor groove of DNA, thereby modulating transcriptional processes critical to cell survival[1][4]. In preclinical models, chromomycin A5 demonstrates potent cytotoxicity against melanoma and other human tumor cell lines. It is a *bona fide inducer of immunogenic cell death (ICD)*, evidenced by its ability to trigger apoptosis, autophagy, ER stress, and the release of danger-associated molecular patterns (DAMPs) including calreticulin, HMGB1, ATP, and ERp57. Immunogenic features were verified in vivo, where CA 5 treatment activated antigen-presenting cells and T lymphocytes, resulting in antitumor immune responses[1][3]. Preliminary studies suggest TBX2 transcription factor modulation as part of its mechanism[4]. Chromomycin A5 is considered a promising investigational agent for advanced metastatic melanoma, currently under preclinical evaluation for antitumor efficacy and immunogenic properties.

Brand names

chromomycin A5

Other names

CA 5CA5CA-5